Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer-Reference-Cited by-同舟云学术

Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer

Published:2018-11-14 Issue:11 Volume:13 Page:e0207224
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Cuello-López Javier^ORCID,Fidalgo-Zapata Ana,López-Agudelo Laura,Vásquez-Trespalacios Elsa

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference39 articles.

1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;P Cortazar;Lancet,2014

2. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657;LJ Esserman;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2012

3. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;G von Minckwitz;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2012

4. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration;V Bossuyt;Annals of oncology: official journal of the European Society for Medical Oncology / ESMO,2015

5. Accelerating identification and regulatory approval of investigational cancer drugs;LJ Esserman;Jama,2011

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High platelet - lymphocyte ratio may predict poor therapeutic response in breast cancer patients treated with neoadjuvant chemotherapy;2024-08-09

2. Associations of three differential white blood cell counts, platelet counts, and their derived inflammatory indices with cancer-related fatigue in patients with breast cancer undergoing chemotherapy;Supportive Care in Cancer;2024-07

3. Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis;British Journal of Surgery;2024-05

4. Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer;The Oncologist;2024-03-02

5. The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients;Clinical and Translational Oncology;2024-01-08